Navigation Links
Denosumab Reduces Bone Erosion

According to results of a 227 patient Phase 2 trial presented at EULAR 2007, the Annual Treatment with denosumab 60 mg and 180 mg (with background methotrexate) reduces the progression of bone erosion .

Denosumab is a fully human monoclonal antibody which binds to and inhibits the RANK Ligand. The RANK Ligand is the essential mediator of osteoclast formation, function, and survival and thereby plays a key role in rheumatoid arthritis (RA) associated bone erosions (osteoclasts are the cells responsible for the break down of bone material).

Bone status in patients hands and feet was assessed by radiographs at initiation of trial, six and 12 months to assess the capacity of denosumab to reduce progression of RA associated bone erosion. Researchers gathered data on erosion score (a measure of damage to joints), joint space narrowing (a measure of reduced space between bones in each joint) and derived the van der Heijde modified Total Sharp Score (TSS)

Professor Desiree van der Heijde of Leiden University Medical Center and lead author of the study commented, These data show the significant potential of denosumab, revealing that patients receiving denosumab experienced a reduced progression of erosions compared to control. Most significant was the difference observed between the control group and the group receiving denosumab 180mg. The reduction in progression of erosions was already present in this group as early as 6 months.

In the double-blind, placebo-controlled, phase 2 study, 227 patients were randomly assigned to receive subcutaneous denosumab injections or placebo at initiation of trial, and after six months, to determine if denosumab could reduce the progression of bone erosions in patients with RA on background methotrexate (MTX standard RA treatment).

Mean erosion scores were significantly reduced for the groups treated with denosumab compared to the control group. Change in mean erosion score at 12 months was reported as 0.33 and 0.19 for treatment with denosumab 60 mg and 180 mg respectively, compared with the change in score for the control group of 1.34 (respective p= 0.01 and p= 0.007).

For the 180mg group the reduction in progression in erosions was already significantly less as compared to the control group after 6 months (0.05 vs. 0.59, p-value = 0.02) and a trend was seen in the 60 mg group (0.25).

An increase in TSS was observed in the control group of patients at 12 months, significantly higher than that observed in patients in the treatment groups. For patients receiving denosumab, the progression in TSS at 12 months was 0.85 and 0.97 for denosumab 60mg and 180mg respectively as compared to 1.87 for the control group (respectively, p=0.03 and p=0.18).

No specific differences in the in Joint Space Narrowing (JSN) were detected between the denosumab and the control groups.In this study, safety was continually monitored and an adverse event profile similar to that of patients receiving placebo was observed in patients receiving treatment with denosumab.


'"/>




Related medicine news :

1. Drug Reduces Risk of Clogged Arteries, Veins
2. Sunshine Reduces MS Risk
3. Estrogen in Food Reduces Cancer Risk
4. Dental Procedure Reduces Preterm Births
5. Vaccine Reduces antibiotic-resistant infections in Children
6. Eating Fiber Reduces The Risk Of Heart Disease
7. Higher Statin Dose Safely Reduces Stroke and Cardiac Arrest
8. Anti-tobacco Advertising Can Reduces smoking Among Teens
9. Eating Fish Reduces Heart Disease
10. Co-trimoxazole Use Reduces Childhood AIDS –Related Death
11. NSAIDS, Reduces The Risk Of Oral Cancer But Causes Heart Attacks
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... ... , ... The American Board of Family Medicine's (ABFM) Board of Directors has ... succeeding Dr. James C. Puffer upon his retirement. Dr. Newton will serve in the ... at the end of 2018. Upon assuming the role of President and CEO on ...
(Date:10/13/2017)... ... , ... Apple Rehab Shelton Lakes , which specializes in the delivery ... as part of a disaster drill on October 3rd. , Apple Rehab participated with ... Manager, as well as the Connecticut Long Term Care Mutual Aid Plan (LTC-MAP). ...
(Date:10/13/2017)... ... 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, ... and least understood books in the Holy Scriptures, Revelation. The Book of Revelation paints ... for centuries. Many have tossed it off as mere rubbish, but Yisrayl Hawkins says ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare Compliance (FHC), an ... showcase a range of technology and learning solutions at the 68th Annual American ... to be held October 14–18, 2017 at the Mandalay Bay Resort in Las ...
(Date:10/12/2017)... ... ... The American College of Medical Informatics (ACMI) will present the 2017 Morris F. ... AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium is taking place ... the field of medical informatics, this prestigious award is presented to an individual whose ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... Cohen Veterans Bioscience and Early Signal Foundation ... and home sensors for real-time monitoring of patients with ... nonprofit organization focused on disruptive health solutions for rare ... system to record and integrate behavioral, cognitive, physiological and ... ...
(Date:9/25/2017)... , Sept. 25, 2017  EpiVax, Inc., ... vaccine design, and immune-engineering today announced the launch ... the development of personalized therapeutic cancer vaccines. EpiVax ... provided exclusive access to enabling technologies to the ... MBA will lead EpiVax Oncology as Chief Executive ...
(Date:9/19/2017)... -- HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy ... team developments today:   ... ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led R&D ...
Breaking Medicine Technology: